Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01811576
Recruitment Status : Completed
First Posted : March 14, 2013
Last Update Posted : February 29, 2016
Information provided by (Responsible Party):
Teva Pharmaceutical Industries

Brief Summary:
The primary objective of this study is to evaluate the clinical effect of TV-1106.

Condition or disease Intervention/treatment Phase
Growth Hormone Deficiency Drug: TV-1106 Drug: Recombinant human growth hormone Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 64-Week (12-week Core Phase and 52-week Safety Extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
Study Start Date : March 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : July 2015

Arm Intervention/treatment
Experimental: TV-1106
Titration dose levels of TV-1106
Drug: TV-1106
Active Comparator: recombinant human growth hormone
Daily subcutaneous dose
Drug: Recombinant human growth hormone
Subcutaneous once daily

Primary Outcome Measures :
  1. Insulin-like growth factor I (IGF-I) concentration change from baseline [ Time Frame: Baseline to Week 12 ]

Secondary Outcome Measures :
  1. Percentage of patients treated with TV1106 who return to pre-treatment IGF-1 SDS [ Time Frame: Baseline to Week 12 ]
  2. Safety Parameters [ Time Frame: 78 weeks ]
    The safety of TV-1106 will be assessed throughout the study by evaluating adverse events,concomitant medication usage, physical examinations including urinalysis and body weight, vital sign measurements, clinical laboratory test results and hormone levels, electrocardiograms (ECGs), and immunogenicity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   23 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient agrees to provide written informed consent and to comply with the study protocol after reading the informed consent and discussing the study with the investigator.
  • Males and females between 23 and 65 years of age must have a confirmed diagnosis of adult GHD, either adult onset (AO) GHD due to hypothalamic-pituitary disease or childhood onset (CO) GHD that is either idiopathic or due to hypothalamic-pituitary disease or due to genetic causes.
  • Diagnosis of GH deficiency must be confirmed by documented (medical records) diagnostic testing.
  • Patients should have been treated with a stable dose of daily rhGH for at least 3 months prior to screening.
  • Other criteria apply.

Exclusion Criteria:

  • Patients with history or clinical evidence of active or chronic diseases that could confound results of the study or put the subject at undue risk as determined by the investigator.
  • Patients with known active malignancy
  • Patients with history of malignancy other than intracranial tumor causing GHD (excluding surgically cured basal cell or squamous cell cancer of the skin with documented 6 month remission)
  • Patients with evidence of pituitary adenoma or other intracranial tumor within 12 months of enrollment, which is on day 0 (baseline, Visit 3)
  • Patients without magnetic resonance imaging (MRI) or computerized tomography (CT) data to document tumor stability within the 12 months prior to enrollment, which is on day 0 (baseline, Visit 3)
  • Presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in the past 1 year.
  • Other criteria apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01811576

United States, Oregon
Teva Investigational Site 10564
Portland, Oregon, United States
Czech Republic
Teva Investigational Site 54051
Olomouc, Czech Republic
Teva Investigational Site 32237
Munich, Germany
Teva Investigational Site 32238
Munich, Germany
Teva Investigational Site 63044
Athens, Greece
Teva Investigational Site 63045
Athens, Greece
Teva Investigational Site 51056
Budapest, Hungary
Teva Investigational Site 51061
Gyor, Hungary
Teva Investigational Site 51059
Pecs, Hungary
Teva Investigational Site 51057
Szeged, Hungary
Teva Investigational Site 51058
Szolnok, Hungary
Teva Investigational Site 80032
Petach Tikva, Israel
Teva Investigational Site 61029
Belgrade, Serbia
Teva Investigational Site 62017
Bratislava, Slovakia
Teva Investigational Site 62022
Bratislava, Slovakia
Teva Investigational Site 62016
Lubochna, Slovakia
Teva Investigational Site 64016
Ljubljana, Slovenia
Sponsors and Collaborators
Teva Pharmaceutical Industries

Responsible Party: Teva Pharmaceutical Industries Identifier: NCT01811576     History of Changes
Other Study ID Numbers: TV1106-GHD-201
2012-004975-37 ( EudraCT Number )
First Posted: March 14, 2013    Key Record Dates
Last Update Posted: February 29, 2016
Last Verified: February 2016

Keywords provided by Teva Pharmaceutical Industries:
Growth hormone deficiency
Insulin-like growth factor I (IGF-I)

Additional relevant MeSH terms:
Dwarfism, Pituitary
Endocrine System Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs